Physician profile
Carol S Cdebaca
NPI 1154518900
$3,814.79
in general payments reported to CMS, 2019-2025
23 companies · $1,234 in 2025
The $1,234 reported for 2025 was more than what 92% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $46.69 · 2023: $1,063 · 2024: $1,471 · 2025: $1,234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,768.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,768.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,156.11 | 2023-2025 | Wavewriter Alpha Prime 16, General - Pain Management, General - Therapies |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $573.99 | 2023-2025 | Relistor |
| Collegium Pharmaceutical, INC. | $419.98 | 2023-2025 | Belbuca, Xtampza |
| Mallinckrodt Hospital Products INC. | $364.39 | 2023-2025 | Acthar |
| Abbvie INC. | $233.01 | 2023-2025 | |
| Pfizer INC. | $162.11 | 2023-2025 | |
| Curonix LLC | $159.36 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Ibsa Pharma INC. | $159.19 | 2023-2025 | Tirosint, Licart, Tirosint |
| Spr Therapeutics, INC | $95.73 | 2024 | Sprint Pns System |
| Vertex Pharmaceuticals Incorporated | $80.20 | 2025 | |
| Si-Bone, INC. | $64.56 | 2023-2024 | |
| Fidia Pharma USA INC. | $58.10 | 2024-2025 | Hymovis |
| Globus Medical, INC. | $44.40 | 2025 | Senza |
| Azurity Pharmaceuticals, INC. | $35.03 | 2024-2025 | Horizant |
| Medtronic, INC. | $32.40 | 2023 | Intellis Adaptivestim, Venaseal |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $31.74 | 2023-2024 | Gelsyn-3 |
| Kowa Pharmaceuticals America, INC. | $29.32 | 2023 | Seglentis |
| Depuy Synthes Sales INC. | $28.05 | 2021 | |
| Amneal Pharmaceuticals LLC | $21.78 | 2023 | Lyvispah |
| Avanos Medical | $21.65 | 2025 | Genvisc 850 Sodium Hyaluronate |
| Convatec INC. | $18.64 | 2021 | |
| Innovation Technologies INC | $16.48 | 2024 | Irrisept |
| Relievant Medsystems, INC. | $8.57 | 2023 | Intracept |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Cdebaca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.